Krystal, Andrew D.
Pizzagalli, Diego A.
Mathew, Sanjay J.
Sanacora, Gerard
Keefe, Richard
Song, Allen
Calabrese, Joseph
Goddard, Andrew
Goodman, Wayne
Lisanby, Sarah H.
Smoski, Moria
Weiner, Richard
Iosifescu, Dan
Nurnberger, John Jr
Szabo, Steven
Murrough, James
Shekhar, Anantha
Potter, William
Article History
First Online: 28 December 2018
Competing interests
: A. Krystal: Consultant: Adare, Eisai, Ferring, Galderma, Idorsia, Jazz, Janssen, Takeda, Merck, Neurocrine, Pernix, Physician's Seal; Research Support: NIH, Janssen, Jazz. Axsome, Reveal Biosensors. D. Pizzagalli: Consulting: Akili Interactive Labs, BlackThorn Therapeutics, Boehreinger Ingelheim, Posit Science and Takeda Pharmaceuticals S. Matthew: Consultant: Allergan, Alkermes, Sage Therapeutics; Research Support: Janssen, NIH, NeuroRx, VistaGen Therapeutics; Drug from Biohaven for NIMH funded study G. Sanacora: Consulting: Allergan, Alkermes, AstraZeneca, Avanier Pharmaceuticals, Axsome Therapeutics Biohaven Pharmaceuticals, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Hoffman La-Roche, Intra-Cellular Therapies, Janssen, Merck, Naurex, Navitor Pharmaceuticals, Novartis, Noven Pharmaceuticals, Otsuka, Praxis Therapeutics, Sage Pharmaceuticals, Servier Pharmaceuticals, Taisho Pharmaceuticals, Teva, Valeant, and Vistagen Therapeutics; Research Funding: AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Hoffman La-Roche, Merck, Naurex, and Servier; Equity Interest: Biohaven Pharmaceuticals; Patent Royalties: Biohaven. J. Murrough: Consultation: Boehreinger Ingelheim, Sage Therapeutics, Novartis, Allergan, Fortress Biotech, Janssen Research and Development, Medavante-Prophase, and Global Medical Education (GME); Research Support: Avanir Pharmaceuticals. R. Keefe: Consultant, Speaker, or Advisory Board Member: Abbvie, Acadia, Aeglea, Akebia, Akili, Alkermes, Allergan, ArmaGen, Astellas, Avanir, AviNeuro/ChemRar, Axovant, Biogen, Boehringer-Ingelheim, Cerecor, CoMentis, Critical Path Institute, FORUM, Gammon Howard & Zeszotarski, Global Medical Education (GME), GW Pharmaceuticals, Intracellular Therapeutics, Janssen, Kempharm, Lundbeck, Lysogene, MedScape, Mentis Cura, Merck, Merrakris Therapetics, Minerva Neurosciences Inc., Mitsubishi, Montana State University, Monteris, Moscow Research Institute of Psychiatry, Neuralstem, Neuronix, Novartis, NY State Office of Mental Health, Orygen, Otsuka, Paradigm Testing, Percept Solutions, Pfizer, Pharm-Olam, Regenix Bio, Reviva, Roche, Sangamo, Sanofi, SOBI, Six Degrees Medical, Sunovion, Takeda, Targacept, Teague Rotenstreich Stanaland Fox & Holt, Thrombosis Research Institute, University of Moscow, University of Southern California, University of Texas Southwest Medical Center, WebMD, and Wilson Therapeutics; Research Funding: The National Institute of Mental Health and Boehringer-Ingelheim; Royalties: Versions of the BAC testing battery, the MATRICS Battery (BACS Symbol Coding), and the Virtual Reality Functional Capacity Assessment Tool (VRFCAT); Shareholder: NeuroCog Trials and Sengenix. S.H. Lisanby: contributed to this article while at Duke University, prior to joining NIMH. The views expressed are her own and do not necessarily represent the views of the National Institutes of Health or the United States Government. Dr Lisanby is a co-inventor on a patent for TMS technology, unrelated to this manuscript. J. Nurnberger: Research Funding: Janssen and Assurex A. Song: Research Support: NIH, GE Healthcare W. Goodman: Consulting: Biohaven Pharmaceuticals; Research funding: NIH, Simons Foundation and Biohaven Pharmaceuticals; Device Donation: Medtronic. A. Goddard: Consultant: UpToDate, Biohaven Pharmaceuticals, Almatica Pharma; Research Funding: National Network of Depression Centers. M. Smoski: None R. Weiner: None. S. Szabo: Consultant: Otsuka Pharmaceuticals, Neurocrine Biosciences, Jazz Pharmaceuticals, Teva Pharmaceuticals, Centers of Psychiatric Excellence, Continuous Precision Medicine; Research Support: Otsuka Pharmaceuticals W. Potter: Advisory Board/Consultant: Takeda, Lilly, Praxis, Astellas, Otsuka and Noven: DSMB: Agene-Bio; Stock Ownership: Merck.